Vnitr Lek 2016, 62(1):44-47

The SPRINT Research. A Randomized Trial of Intensive versus Standard Blood-Pressure Control

Jiří Widimský
Klinika kardiologie IKEM, Praha

Background:
The most appropriate targets for systolic blood pressure to reduce cardiovascular morbidity and mortality among persons without diabetes remain uncertain.

Methods:
We randomly assigned 9 361 persons with a systolic blood pressure of 130 mm Hg or higher and an increased cardiovascular risk, but without diabetes, to a systolic blood-pressure target of less than 120 mm Hg (intensive treatment) or a target of less than 140 mm Hg (standard treatment). The primary composite outcome was myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes.

Results:
At 1 year, the mean systolic blood pressure was 121.4 mm Hg in the intensive treatment group and 136.2 mm Hg in the standard-treatment group. The intervention was stopped early after a median follow-up of 3.26 years owing to a significantly lower rate of the primary composite outcome in the intensive-treatment group than in the standard-treatment group (1.65 % per year vs 2.19 % per year; hazard ratio with intensive treatment, 0.75; 95% confidence interval (CI) 0.64 to 0.89; p < 0.001). All causes mortality was also significantly lower in the intensive-treatment group (hazard ratio, 0.73; 95% CI 0.60 to 0.90; p = 0.003). Rates of serious adverse events of hypotension, syncope, electrolyte abnormalities, and acute kidney injury or failure, but not of injurious falls, were higher in the intensive-treatment group than in the standard-treatment group.

Conclusions:
Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group. Funded by the National Institutes of Health.

Keywords: intensive treatment of hypertension; rates of serious adverse; SPRINT

Received: November 29, 2015; Accepted: December 15, 2015; Published: January 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Widimský J. The SPRINT Research. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. Vnitr Lek. 2016;62(1):44-47.
Download citation

References

  1. Wright JT, Williamson PK, Snyder JK et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015; 373(22): 2103-2116. Go to original source... Go to PubMed...
  2. Perkovic V, Rodgers A. Redefining Blood-Pressure Targets - SPRINT starts the Marathon. N Engl J Med 2015; 373(22): 2175-2178. Go to original source... Go to PubMed...
  3. Drazen JM, Morrissey S, Campion EW et al. A SPRINT to the Finish. N Engl J Med 2015; 373(22): 2174-2175. Go to original source... Go to PubMed...
  4. Yeh JS, Bakris GL, Taler SJ. CLINICAL DECISIONS. Blood-Pressure Control. N Engl J Med 2015; 373(22): 2180-2182. Go to original source... Go to PubMed...
  5. ACCORD Study Group, Cushman WC, Evans GW et al. Effect of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1575-1585. Go to original source... Go to PubMed...
  6. Cushman WC, Evans GW, Cutler JA. Long-term cardiovascular effects of 4.9 years of intensive blood pressure control in type 2 diabetes mellitus: The Action to Control Cardiovascular Risk in Diabetes: follow-on blood-pressure study. American Heart Association 2015 Scientific Sessions: 2015. Orlando (FL). Abstract. Dostupné z WWW: <https://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_478891.pdf>.
  7. Chobanian AV. Time to ASSESS Blood-Pressure Goals. N Engl J Med 2015; 373(22): 2093-2095. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.